TibaRay Awarded $400K Contract from the National Cancer Institute for Ultra-Rapid FLASH Beam Monitoring and Control Technology Development

The National Cancer Institute recently awarded TibaRay a $400K contract to develop a highly sensitive and ultra-fast radiation therapy (RT) FLASH dosimetry monitoring and control system. Conventional dose monitoring devices demonstrate non-linear behavior when used for FLASH RT applications, demanding the development of novel state-of-the-art hardware capable of measuring and controlling FLASH dose rates that are two to three orders of magnitude higher than conventional RT doses. Inclusive of this contract, TibaRay has now received funding of more than $10M from the Department of Energy and the National Institute of Health.

TibaRay’s novel radio frequency-based beam monitor will be integrated directly onto one of the Company’s FLASH linear accelerators. Using this proprietary hardware, the RT dosimetry system will be developed to provide the capability to not only digitally measure beam intensity, pulse-by-pulse, on a sub-microsecond time scale but also demonstrate control of the beamline. TibaRay will collaborate with Stanford University as part of this contract.

“As a company operating at the intersection of radio frequency technology and the medical device market, TibaRay is uniquely positioned to fill this gap by pioneering the industry’s most sensitive and rapid FLASH dosimetry monitoring and control system. We are honored to be selected by the National Cancer Institute to deliver this critical technology required for the successful deployment of any FLASH treatment system,” said Arun Ganguly, PhD, Principal Investigator, Chief Technology Officer, and Chief Operations Officer, of TibaRay.